Stock 002332 ZHEJIANG XIANJU PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Zhejiang Xianju Pharmaceutical Co.,Ltd.

Equities

002332

CNE100000K64

End-of-day quote Shenzhen S.E.
Other stock markets
 18:00:00 2024-05-30 EDT 		5-day change 1st Jan Change
12.16 CNY -0.82% Intraday chart for Zhejiang Xianju Pharmaceutical Co.,Ltd. -1.94% -4.78%
05-30 Zhejiang Xianju Pharmaceutical Co.,Ltd. Announces 2023 Final Profit Distribution on A Shares, Payable on 05 June 2024 CI
05-22 Zhejiang Xianju Pharmaceutical Co.,Ltd. Approves Cash Dividend for the Year 2023 CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 54% by 2026.
  • The company returns high margins, thereby supporting business profitability.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
ZHEJIANG XIANJU PHARMACEUTICAL CO.,LTD. Stock Zhejiang Xianju Pharmaceutical Co.,Ltd.
-4.78% 1.66B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
B-
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
B+
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
A+
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
C+
PFIZER, INC. Stock Pfizer, Inc.
-0.45% 162B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 002332 Stock
  4. Ratings Zhejiang Xianju Pharmaceutical Co.,Ltd.